The pharmacokinetic properties of mezlocillin were evaluated in newborn infants. Mean peak and trough concentrations of drug in plasma, after 75 mg of mezlocillin per kg given intravenously, were 252 and 72 JLg/ ml, respectively, in infants who were <38 weeks gestation and s7 days old, compared with 139 and 9 ,ug/ml, respectively, in infants .38 weeks gestation and >7 days old. The mean elimination half-life values were from 4.5 h in preterm infants who were <7 days old to 1.8 h in term infants .7 days old. Median peak and trough bactericidal titers of drug in plasma from neonates treated with mezlocillin were 1:8 and 1:4, respectively, against a resistant (minimal bactericidal concentration, 512 ,ug/ml) Escherichia coli strain and 1:64 and 1:32, respectively, against a susceptible (minimal bactericidal concentration, 2 ,ug/ml) E. coli strain. We propose a dosage schedule of 75 mg of mezlocillin per kg administered every 12 h to preterm (gestational age <38 weeks) infants c7 days old, every 8 h to preterm infants >7 days old or term infants -7 days old, and every 6 h to term infants >7 days old.
Previous studies from our laboratory showed that the bacteriological efficacy of mezlocilin in experimental Escherichia coli meningitis in rabbits was comparable to that of moxalactam (11) and ceftazidime (10) and superior to that of netilmicin (11) . In experimental Listeria meningitis, mezlocillin and ampicillin were comparably effective in reducing the number of bacteria in cerebrospinal fluid (CSF) (7) . An unexpected finding was that the in vitro activity of mezlocillin against five resistant strains of gram-negative enteric bacilli was enhanced many fold by the addition of fresh rabbit serum to Mueller-Hinton broth (1) . This effect was destroyed by heating the broth-serum mixture at 60°C for 30 min. A possible in vivo correlary of these in vitro data was the observation that a single dose of 100 mg of mezlocillin per kg given to rabbits with experimental meningitis due to a mezlocillin-resistant (minimal bactericidal concentration [MBC] , 512 ,ug/ml) strain of E. coli produced a 1:64 serum bactericidal titer against the organism and sterilized CSF cultures of all five animals infected with this resistant strain (7) .
On the basis of these observations in experimentally infected animals and of the broad in vitro activity of mezlocillin against the majority of pathogens responsible for neonatal infections, the following study in newborn infants was undertaken. We determined the pharmacokinetics and bactericidal activity of mezlocillin in plasma of infants of different gestational and postnatal ages. were collected by the heel-stick technique at 0, 0.5, 1, 2, 4, and 8 h after the end of the 10-min intravenous (i.v.) infusion, and the plasma separated therefrom was stored at -70°C until assayed within 24 to 72 h. From one to three doses of mezlocillin were given before the first samples were collected. In 11 patients, blood specimens were collected on two occasions: the first after mezlocillin was given i.v. and the second after it was given intramuscularly (i.m.). In an additional 15 infants, from 2 to 30 doses (mean, 8 doses) were given, and plasma concentrations were measured during or at completion of therapy to assess tolerance to the drug and if accumulation in plasma occurred. The drug was given every 12 h to infants <7 days of age and every 8 h thereafter.
MATERIALS AND METHODS
Meziocillin assay. Concentrations of mezlocillin in plasma were measured by an agar disk diffusion micromethod with Bacillus subtilis (Difco Laboratories; 6453-36) as the test organism. The lowest concentration measured by this technique was 1.25 ,ug/ml. The samples and standards were diluted in 100lo pooled human plasma. The intraassay coefficient of variation with 20 measurements of the reference standard was 4.83%. The interassay coefficient of variation determined in a 6-week period in which the reference standard was measured 34 times was 11.16%. Gentamicin activity in plasma was inactivated by the addition of 3% sodium chloride to the agar; this procedure had no effect on mezlocillin activity. The half-life in hours was determined by dividing the natural log of 2 by the slope (K) of the plasma concentration-versustime curve The volume of distribution expressed in milliliters per kilogram was calculated by the formula Vd = dosage (milligrams per kilogram)/AUC x K, and the area under the plasma concentration-time curve (AUC) in micrograms per milliliter x hours was obtained by successive trapezoidal approximations from t = 0 to t = oc (8) .
(ii) Two-compartment open-system kinetic model. The twophase decline in concentrations of drug in plasma (Cp) was determined by the NONLIN least-squares regression computer program (5). It was fitted by the biexponential equation patients), and 8 ± 7 ,ug/ml (dose 13, 3 patients). Accumulation in plasma was not noted in any study infant.
The one-and two-compartment pharmacokinetics from the plasma concentration-versus-time curves were determined for each infant. The best compartment fit for each curve was selected on the basis of the calculated coefficient of variation. The curves of 19 (73%) of 26 infants who were <38 weeks gestation and c7 days of age, of 5 (38%) of 13 infants .38 weeks gestation and c7 days of age, and of 3 (38.9%) of 8 infants .38 weeks gestation and >7 days were best described by the two-compartment model. The mean a or distribution half-lives in these 27 infants in whom twocompartment pharmacokinetics applied were from 0.16 to 0.61 h ( Table 2 ). The mean ,B or elimination half-life values in all 47 infants were from 4.5 h in premature infants who were c7 days old to 1.6 h in term infants who were >7 days old. The plasma clearance values were inversely correlated with half-life and increased with increasing gestational and postnatal ages. The mean volume of drug distribution values was from 343 ml/kg in premature infants who were c7 days old to 420 ml/kg in term infants who were >7 days old. The values for the volume of distribution correlated inversely with the peak concentrations of mezlocillin in plasma. The bioavailability (based on AUC values) of mezlocillin after i.m. administration was smaller than that after i.v. administration.
Bactericidal titers. Bactericidal titers against a mezlocillinresistant and a mezlocillin-susceptible strain of E. coli were determined in 76 plasma specimens obtained from 47 newborn infants who received mezlocillin either alone or with gentamicin (Table 3) . Despite mezlocillin concentrations in plasma that were less than one-half the MBC of the resistant E. coli strain, peak bactericidal titers were from 1:4 to 1:32 (median 1:8 after i.v. infusion and 1:4 after i.m. dose), and median trough titers were 1:4 and 1:2, respectively. The titers were considerably larger against the susceptible E. coli strain, and the median peak and trough titers after i.v. administration were 1:64 and 1:32, respectively. Titers in specimens from infants who received mezlocillin and gentamicin were two-to fourfold larger than those in infants given mezlocillin alone. Plasma samples from mezlocillin-treated newborn infants had peak bactericidal titers against a mezlocillin-resistant E. coli strain of from 1:4 to 1:32 (median titer, 1:8) and trough titers of from 1:2 to 1:8 (median titer, 1:4), after i.v. administration. The mean concentrations of mezlocillin in these plasma samples were from 10 to 43% of the MBC (512 ,ug/ml) for this strain. These inordinately large plasma bactericidal titers relative to the concentrations of mezlocillin in plasma and the MBC of the E. coli strain used in the test may be a result of the interaction of plasma with mezlocillin. We previously demonstrated similar bactericidal titers in rabbits infected with this E. coli strain and ascribed this finding to a synergistic interaction between fresh rabbit serum and mezlocillin that was abolished by heating the plasma at 60°C for 30 min. (3, 7) . In this meningitis model, single doses of 100 mg of mezlocillin per kg reduced the numbers of resistant E. coli in CSF by -4.9 log10 CFU per ml in 5 h and sterilized the CSF cultures in all five rabbits despite the absence of CSF bactericidal activity.
On the basis of tnese pharmacokinetic data and on the preliminary experience of Chiu and associates (2), mezlocillin should be evaluated for therapy of neonatal bacterial diseases. We recommend that doses of 75 mg of mezlocillin per kg be given approximately every third plasma half-life (i.e., t 1/2p) to maintain peak concentrations in plasma at 30 to 60 min after administration above 100 ,ug/ml and trough (predose) concentrations above 10 to 15 p.g/ml. The dosage schedule would be 75 mg/kg administered every 12 h to preterm infants s7 days old, every 8 h to preterm infants >7 days old or term infants <7 days old, and every 6 h to term infants >7 days old. This regimen is similar to that recommended for ticarcillin, which has comparable pharmacokinetic properties in newborn infants (6) . At present, ampicillin and an aminoglycosidic drug are routinely used as initial therapy for sepsis and meningitis in newborn infants. Mezlocillin combined with an aminoglycoside may be a more logical combination to use initially, but additional clinical studies are required before such a regimen can be recommended.
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